comparemela.com

Latest Breaking News On - Available methods - Page 1 : comparemela.com

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs placebo in LAURA Phase III trial

WILMINGTON, Del. (BUSINESS WIRE) Jun 2, 2024

United statesUnited kingdomChelsea tresslerDaiichi sankyoBrendan mcevoyAmerican society of clinical oncologyWorld health organizationLungevity foundationLung ambition allianceInternational agency for research on cancerArchives pathology labSingle institution studyPlenary sessionClinical oncologyAnnual meetingNew england journal

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting .

United statesUnited kingdomSuresh ramalingamSusan galbraithCerner cancermpactDaiichi sankyoInternational agency for research on cancerAmerican cancer societyLung ambition allianceWinship cancer institute of emory universityLungevity foundationSingle institution studyWorld health organisationExecutive directorWinship cancer instituteEmory university

Complying with the Children s Online Privacy Protection Rule; FTC s Proposed Updates | Kilpatrick

On December 20, 2023, the Federal Trade Commission (FTC) published a Notice of Proposed Rulemaking (Proposed Rule) seeking to update the Children’s Online Privacy Protection Act.

School for educational servicesSchool authorizationFederal trade commissionProposed rulemakingProposed ruleOnline privacy protection actAudience sitesDirected standard changesPersonal informationThird partiesAvailable methodsObtaining opt in consentEducational servicesAuthorized education purposeSecurity requirementsDeletion requirements

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

WILMINGTON, Del. (BUSINESS WIRE) Oct 16, 2023

United kingdomUnited statesSusan galbraithBrendan mcevoyDaiichi sankyoChelsea fordWorld health organisationInternational agency for research on cancerLungevity foundationSingle institution studyLung ambition allianceDrug administrationNew drug applicationPriority reviewPrescription drug user fee actExecutive vice president

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care .

United kingdomUnited statesDaiichi sankyoSingle institution studyLung ambition allianceCompany on social media astrazenecaLungevity foundationWorld health organisationInternational agency for research on cancerPresidential symposiumInternational associationLung cancerPrescribing informationPatient informationSouth americaRare diseases

vimarsana © 2020. All Rights Reserved.